New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 27, 2011
14:07 EDTMRKEarnings Preview: Merck trading up ahead of Q3 earnings
Merck (MRK) is expected to report Q3 earnings before the market open on Friday, October 28 with a conference call scheduled for 8:00 am ET. Analysts are looking for EPS of 91c on revenue of $11.61B. The consensus range is 83c-93c for EPS, and $11.47B-$11.95B for revenue, according to First Call. In Q2, Merck reported in-line EPS and better-than-expected revenue. It also reported sales growth for Singular, Remicade, and Animal Health, while raising the full-year EPS to $3.68-$3.76. In its previous conference call, the company announced plans to reduce the workforce by 12%-13% by 2015. The measure would save the company $3.5B by the end of FY12. To accelerate the goal, the Associated Press reported the company may speed up the layoffs to reach that goal. In the previous quarter, Merck announced positive clinical results for several drugs: Isentress, Delura, Odanacatib, and Gardasil. In fact, the CDC voted to expand the use of Gardasil. Investors will also look for updates on the progress of its new type 2 diabetes treatment Juvisync, which recently received FDA approval. Meanwhile, the company signed various research and colloboration agreements with AbD Serotec, Serum Institute of India, and BGI. The company may also mention its sale of its 50% interest in the Johnson & Johnson-Merck joint venture for $175M. Merck was upgraded to Buy at Jeffries, citing valuation and capital allocation. Barron's also said Merck was attractive for its dividend yield, restructuring savings, and expansion in emerging markets.
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
08:05 EDTMRKTetraLogic, Merck enter into oncology clinical study collaboration
Subscribe for More Information
07:20 EDTMRKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 19, 2015
19:35 EDTMRKMerck to swiftly repay $5B loan, explore acquisitions by late 2017, Reuters says
Subscribe for More Information
15:21 EDTMRKMerck announces new data from Keytruda study
Subscribe for More Information
14:59 EDTMRKMerck's Keytruda 'superior' to ipilimumab for PFS in patients with melanoma
Subscribe for More Information
14:47 EDTMRKMerck submits supplemental biologics license for Keytruda in lung cancer
Subscribe for More Information
14:31 EDTMRKMerck reports 28% Keytruda response rate in 25 pleural mesothelioma patients
Subscribe for More Information
April 15, 2015
08:33 EDTMRKFDA panel results positive for Merck, says SunTrust
Subscribe for More Information
April 14, 2015
13:32 EDTMRKMerck, NewLink Genetics confirm initiation of Phase 3 trial of Ebola vaccine
Subscribe for More Information
April 13, 2015
08:58 EDTMRKMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
April 9, 2015
09:25 EDTMRKPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
April 8, 2015
07:33 EDTMRKAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
April 7, 2015
07:14 EDTMRKEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use